Long-Acting ADHD Meds for Anxious Adult Patients
When choosing the right treatment for depression or anxiety, patients often weigh the benefits and side effects of different medications. Both of these selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed and have proven effective for mood disorders. The choice between Zoloft vs Lexapro can depend on individual response, side effects, or coexisting conditions. While one may work better for generalized anxiety, the other might be preferred for major depression. Consulting a healthcare provider is essential to determine which medication suits each person's unique needs, as both options offer relief but may differ in tolerability and onset of action.
ADHD and anxiety disorders often co-occur in adults. In fact, it's estimated that nearly 50% of adults with ADHD also experience an anxiety disorder. These conditions can amplify one another: the inattention and disorganization caused by ADHD may increase stress levels, while anxiety can worsen the ability to focus and complete tasks. Treating both conditions at once can be challenging, especially when using stimulant medications, which can sometimes increase anxiety symptoms. Therefore, choosing the right treatment is crucial to ensuring balanced mental health.
Long-acting ADHD medications offer several benefits for anxious adult patients. Unlike short-acting versions, which may wear off in a few hours and cause a crash in mood or energy, long-acting medications provide a smoother, extended release of active ingredients. This consistent delivery helps reduce the peaks and valleys that can trigger anxiety or mood disturbances. For adults who work full-time or have complex daily responsibilities, these medications can maintain focus, organization, and emotional regulation throughout the day without the need for multiple doses.
There are several long-acting ADHD medications available, many of which are formulated to release their active ingredient slowly over time. Commonly prescribed long-acting stimulants include Concerta (methylphenidate), Adderall XR (amphetamine salts), Vyvanse (lisdexamfetamine), and Focalin XR (dexmethylphenidate). These medications can be effective for up to 10 to 14 hours, providing full-day symptom management. For patients sensitive to stimulants or prone to anxiety, non-stimulant options like Strattera (atomoxetine) or Qelbree (viloxazine) may be preferred, as they are less likely to increase nervousness or jitteriness.
Vyvanse is a widely used long-acting stimulant that is often well-tolerated by anxious patients. Its mechanism of action involves the gradual conversion of the prodrug lisdexamfetamine into its active form, which leads to a more predictable and sustained effect. This gradual release can reduce the risk of a sudden onset of stimulant side effects such as irritability or restlessness. Because it has a lower potential for abuse and misuse, it's also considered a safer choice for long-term treatment in adults with a history of anxiety or mood instability.
Strattera, or atomoxetine, is a non-stimulant medication approved for ADHD treatment in both children and adults. For anxious patients, Strattera can be particularly beneficial because it doesn't carry the same risk of increasing anxiety as stimulant medications might. It works by selectively inhibiting the reuptake of norepinephrine, which can help improve focus and attention without inducing the overstimulation that sometimes exacerbates anxiety. It typically takes several weeks to reach full effectiveness, but the trade-off may be worth it for those who need a gentler approach to symptom control.
Qelbree (viloxazine) is a newer non-stimulant ADHD medication that has shown promise in managing symptoms in adults. Early studies suggest that it can help with inattention and hyperactivity without significantly raising anxiety levels. Its once-daily dosing and extended-release profile make it a convenient option for busy adults. Although it is not yet as commonly prescribed as other long-acting medications, Qelbree may become a go-to choice for patients who are unable to tolerate stimulants or who have significant comorbid anxiety.
Treating adults with both ADHD and anxiety requires a nuanced approach. While stimulant medications are the most effective for core ADHD symptoms, they must be used cautiously in those prone to anxiety. Clinicians often start with lower doses and gradually increase as needed, closely monitoring anxiety levels. In some cases, a combination of medications may be necessary—such as using a long-acting stimulant alongside an anti-anxiety medication or antidepressant. Non-pharmacologic interventions like cognitive-behavioral therapy (CBT) also play a key role in comprehensive care.
Although long-acting ADHD medications are generally well-tolerated, they can still cause side effects, especially in sensitive individuals. Common side effects include insomnia, appetite suppression, elevated heart rate, and increased anxiety. Regular follow-up with a healthcare provider is important to monitor for these issues and adjust the dosage or medication as needed. Patients are encouraged to keep a symptom journal to track their response and communicate any concerns with their doctor.
Long-acting ADHD medications offer a valuable option for adults dealing with both ADHD and anxiety. With their stable release mechanisms and all-day symptom control, they can help patients achieve better focus and emotional balance without the frequent dosing or mood swings associated with short-acting options. Whether through stimulant or non-stimulant medications, personalized treatment plans that consider anxiety symptoms can make a significant difference in daily functioning and overall quality of life. As always, working closely with a knowledgeable healthcare provider is essential to finding the most effective and tolerable medication strategy.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
5 hours ago
- New York Post
The 4 new subtypes of autism explained
Autism rates are on the rise, with diagnoses in the US jumping 175% between 2011 and 2022. While that's due to a combination of factors — including changing guidelines for diagnosis and more young adults seeking answers about themselves — it's also ramped up the need for better understanding in how to care for those on the spectrum. Now groundbreaking new research from Princeton University and the Simons Foundation has pinpointed four distinct subtypes of autism, which are characterized not just by behavior but biological differences. 'Understanding the genetics of autism is essential for revealing the biological mechanisms that contribute to the condition, enabling earlier and more accurate diagnosis, and guiding personalized care,' said senior study author Olga Troyanskaya, director of Princeton Precision Health. She and her fellow researchers used data from over 5,000 children and published their findings in Nature Genetics. The four new subtypes are: Social and Behavioral Challenges People in this group show 'core autism traits, including social challenges and repetitive behaviors, but generally reach developmental milestones at a pace similar to children without autism,' according to Princeton University. They're also likely to have other psychiatric conditions, including ADHD, anxiety, depression or obsessive-compulsive disorder. This is the largest group, making up 37% of study participants. Mixed ASD with Developmental Delay This group 'tends to reach developmental milestones, such as walking and talking, later than children without autism, but usually does not show signs of anxiety, depression or disruptive behaviors.' The reason they're 'mixed' is because of differences with repetitive behaviors and social challenges. This group made up 19% of the study. Moderate Challenges These people also show core autism-related behaviors, 'but less strongly than those in the other groups, and usually reach developmental milestones on a similar track to those without autism.' They also don't typically have psychiatric issues. This group made up 34% of participants. 3 Sergey Nivens – Broadly Affected The smallest group — comprising just 10% of study participants — is also the most severe. They face 'more extreme and wide-ranging challenges, including developmental delays, social and communication difficulties, repetitive behaviors and co-occurring psychiatric conditions like anxiety, depression and mood dysregulation.' How did they find these subtypes — and what they learn about their genetics? Kids in the study were evaluated on 230 traits, then split into groups based on the most common combinations. Once the groups were defined, the scientists could link them to 'distinct underlying biology,' according to Aviya Litman, a Ph.D. student at Princeton and co-lead author. But the way autism unfolds within these groups — and how biology comes into play — differs. All of these subtypes have genetic disruptions that impact brain development. But when those genetic disruptions activate is different from subtype to subtype. Previously, experts believed that it mostly happened before birth — but for people in the Social and Behavioral Challenges group, some gene mutations became active later on. That doesn't mean that that the genes mutated later on due to external factors, but that the expression of that mutated gene doesn't happen until further into childhood. What does this mean for treatment and care? Knowing the subtype your child falls into can also help you choose better care for them. 'It could tell families, when their children with autism are still young, something more about what symptoms they might — or might not — experience, what to look out for over the course of a lifespan, which treatments to pursue, and how to plan for their future,' said study co-author Jennifer Foss-Feig, a clinical psychologist at the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai.
Time Business News
a day ago
- Time Business News
Long-Acting ADHD Meds for Anxious Adult Patients
Attention Deficit Hyperactivity Disorder (ADHD) is commonly associated with children, but it also significantly affects adults. Many adults with ADHD also experience comorbid anxiety disorders, which can complicate both diagnosis and treatment. For this group of patients, managing symptoms effectively while minimizing anxiety is essential. One promising solution is the use of long-acting best adhd medication for adults with anxiety medications. These medications provide stable symptom control throughout the day with fewer mood swings, making them a favorable option for adults who are also struggling with anxiety. When choosing the right treatment for depression or anxiety, patients often weigh the benefits and side effects of different medications. Both of these selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed and have proven effective for mood disorders. The choice between Zoloft vs Lexapro can depend on individual response, side effects, or coexisting conditions. While one may work better for generalized anxiety, the other might be preferred for major depression. Consulting a healthcare provider is essential to determine which medication suits each person's unique needs, as both options offer relief but may differ in tolerability and onset of action. ADHD and anxiety disorders often co-occur in adults. In fact, it's estimated that nearly 50% of adults with ADHD also experience an anxiety disorder. These conditions can amplify one another: the inattention and disorganization caused by ADHD may increase stress levels, while anxiety can worsen the ability to focus and complete tasks. Treating both conditions at once can be challenging, especially when using stimulant medications, which can sometimes increase anxiety symptoms. Therefore, choosing the right treatment is crucial to ensuring balanced mental health. Long-acting ADHD medications offer several benefits for anxious adult patients. Unlike short-acting versions, which may wear off in a few hours and cause a crash in mood or energy, long-acting medications provide a smoother, extended release of active ingredients. This consistent delivery helps reduce the peaks and valleys that can trigger anxiety or mood disturbances. For adults who work full-time or have complex daily responsibilities, these medications can maintain focus, organization, and emotional regulation throughout the day without the need for multiple doses. There are several long-acting ADHD medications available, many of which are formulated to release their active ingredient slowly over time. Commonly prescribed long-acting stimulants include Concerta (methylphenidate), Adderall XR (amphetamine salts), Vyvanse (lisdexamfetamine), and Focalin XR (dexmethylphenidate). These medications can be effective for up to 10 to 14 hours, providing full-day symptom management. For patients sensitive to stimulants or prone to anxiety, non-stimulant options like Strattera (atomoxetine) or Qelbree (viloxazine) may be preferred, as they are less likely to increase nervousness or jitteriness. Vyvanse is a widely used long-acting stimulant that is often well-tolerated by anxious patients. Its mechanism of action involves the gradual conversion of the prodrug lisdexamfetamine into its active form, which leads to a more predictable and sustained effect. This gradual release can reduce the risk of a sudden onset of stimulant side effects such as irritability or restlessness. Because it has a lower potential for abuse and misuse, it's also considered a safer choice for long-term treatment in adults with a history of anxiety or mood instability. Strattera, or atomoxetine, is a non-stimulant medication approved for ADHD treatment in both children and adults. For anxious patients, Strattera can be particularly beneficial because it doesn't carry the same risk of increasing anxiety as stimulant medications might. It works by selectively inhibiting the reuptake of norepinephrine, which can help improve focus and attention without inducing the overstimulation that sometimes exacerbates anxiety. It typically takes several weeks to reach full effectiveness, but the trade-off may be worth it for those who need a gentler approach to symptom control. Qelbree (viloxazine) is a newer non-stimulant ADHD medication that has shown promise in managing symptoms in adults. Early studies suggest that it can help with inattention and hyperactivity without significantly raising anxiety levels. Its once-daily dosing and extended-release profile make it a convenient option for busy adults. Although it is not yet as commonly prescribed as other long-acting medications, Qelbree may become a go-to choice for patients who are unable to tolerate stimulants or who have significant comorbid anxiety. Treating adults with both ADHD and anxiety requires a nuanced approach. While stimulant medications are the most effective for core ADHD symptoms, they must be used cautiously in those prone to anxiety. Clinicians often start with lower doses and gradually increase as needed, closely monitoring anxiety levels. In some cases, a combination of medications may be necessary—such as using a long-acting stimulant alongside an anti-anxiety medication or antidepressant. Non-pharmacologic interventions like cognitive-behavioral therapy (CBT) also play a key role in comprehensive care. Although long-acting ADHD medications are generally well-tolerated, they can still cause side effects, especially in sensitive individuals. Common side effects include insomnia, appetite suppression, elevated heart rate, and increased anxiety. Regular follow-up with a healthcare provider is important to monitor for these issues and adjust the dosage or medication as needed. Patients are encouraged to keep a symptom journal to track their response and communicate any concerns with their doctor. Long-acting ADHD medications offer a valuable option for adults dealing with both ADHD and anxiety. With their stable release mechanisms and all-day symptom control, they can help patients achieve better focus and emotional balance without the frequent dosing or mood swings associated with short-acting options. Whether through stimulant or non-stimulant medications, personalized treatment plans that consider anxiety symptoms can make a significant difference in daily functioning and overall quality of life. As always, working closely with a knowledgeable healthcare provider is essential to finding the most effective and tolerable medication strategy. TIME BUSINESS NEWS
Medscape
a day ago
- Medscape
ADHD in UK Prisons: A Failing System of Care?
In the early 1990s, while working at the Maudsley Hospital in London, clinical and forensic psychologist Susan Young began to notice a troubling trend. Young people diagnosed with conditions such as attention deficit hyperactivity disorder (ADHD) were missing appointments, only to resurface months later. Many sheepishly admitted that they had been in prison. 'Of course it was not a huge surprise, because around 50% of children with ADHD will also have conduct problems. That's been known for many years,' Young told Medscape News UK . 'Not all of them will go on to have careers in crime and many will get off that path,' but many will continue, she added. Susan Young Young, who now runs a private practice, has been researching the link between ADHD and criminal behaviour ever since. She was the lead author of one of the first meta-analyses examining ADHD prevalence among incarcerated populations. Is it One in Four? Published in Psychological Medicine a decade ago, Young's meta-analysis found that approximately 25% of prisoners met diagnostic criteria for ADHD. A subsequent meta-analysis, published in Frontiers Psychiatry , calculated the prevalence at around 26%. The figures suggested ADHD rates among prisoners were five to 10 times higher than in the general population. The National Institute for Health and Care Excellence (NICE) currently estimates ADHD affects 3%-4% of adults and 5% of children and young people. However, more recent data have challenged the estimate of one in four. A 2024 meta-analysis by Professor Seena Fazel of the University of Oxford and Dr Louis Favril from Ghent University, published in Criminal Behaviour and Mental Health , put the figure closer to 8%, or possibly lower. Fazel has attributed the earlier estimates to methodological issues in previous studies, including reliance on self-reported symptoms and selected sampling. 'If a screen was followed by a more detailed assessment (2-phase design), prevalence was systematically higher,' he wrote. 'We think it may be related to a form of confirmation bias or (medication and other perceived) consequences from this diagnosis in prison.' The Numbers Behind the Debate Regardless of whether the rate is 25% or 8%, the figures are sobering. According to Ministry of Justice (MoJ) and HM Prison & Probation Service (HMPPS) data, more than 325,000 individuals were in the criminal justice system in England and Wales as of 31 December 2024. This includes 85,372 prisoners and 240,497 people on probation. A 25% prevalence rate would suggest over 81,000 people with ADHD are involved in the system; even an 8% rate equates to at least 26,000 individuals. 'Certainly lots of young offenders appear to have ADHD,' said Professor Philip Asherson, emeritus professor at King's College London and a director of the UK Adult ADHD Network that provides support, education, and training for professionals who work with adults with ADHD. Professor Philip Asherson 'There's a question about how to identify ADHD early and give people the right kind of support for their ADHD and their behaviour, to try and direct them away from the criminal justice service,' the recently retired psychiatrist told Medscape News UK . ADHD and the Path to Offending NICE defines ADHD as a neurodevelopmental condition characterised by persistent inattention hyperactivity, or impulsivity that interferes with functioning or development. Asherson, who was a member of NICE's ADHD guideline development group, said the condition 'generates emotional instability, impulsive behaviour, and is associated with difficulty attending [school]. So it's hard for people to learn, to do well in education.' He noted that many individuals with ADHD struggle academically, a pattern also seen widely in prison populations. MoJ data from 2022-2023 indicate that 28% of prisoners had a confirmed learning difficulty or disability. Limited education and few life opportunities, coupled with undiagnosed ADHD, may lead some young people to land on the wrong side of the law, Asherson observed. 'In the prison I worked in, a lot of them were drug dealers or linked in some way to drug-related activity,' he said. 'I guess that was a way of functioning or making money if you were unable to hold down a job and were poorly educated.' ADHD and Reoffending Risk Research has also shown that 96% of prisoners with ADHD have at least one comorbidity, Young said. 'If you compare prisoners with ADHD to prisoners without ADHD, and you look at the comorbidity, they have higher rates of everything. They have more severe anxiety, more severe depression.' Young, who is also an honorary professor at Reykjavik University in Iceland, also noted: 'They're revolving door criminals, because they're going in and out, in and out [of prison].' Young and other researchers have reported that prisoners with ADHD are more likely to reoffend, enter the criminal justice system earlier, make false confessions, and engage in risky behaviours such as substance misuse. Misunderstood and Misdiagnosed Young, alongside Kelly Cocallis from Northumbria Healthcare NHS Foundation Trust, highlighted that offenders with ADHD are 'disadvantaged within the system.' They are disadvantaged because ADHD symptoms are often under recognised and/or misunderstood and their diagnosis of ADHD 'may be missed or misdiagnosed.' This was the experience of Jan (not her real name), an ex-offender supported by Working Chance, a charity which helps women with criminal records find employment. As soon as you walk into the prison, it's like you're cut off from society and everything stops Jan was initially diagnosed with emotionally unstable personality disorder. 'When I looked into it more, I didn't think the diagnosis was right,' she told Medscape News UK . She eventually sought a private ADHD assessment in 2018. By then, her life was already in crisis, embroiled in court proceedings that resulted in her children being taken into care. Jan had to wait until 2021 for the NHS to confirm the ADHD diagnosis. It was too late to avoid a cascade of events: poor educational performance, teenage pregnancy, a string of abusive relationships, and, finally, a criminal conviction. 'I was quite vulnerable at the time of my offence,' Jan said. 'Because I hadn't really felt affection and was in a vulnerable place, it all added up. I feel like if I'd been able to manage my emotions, which is hard with ADHD, I potentially wouldn't have ended up in that situation. The decision-making would have been slightly different.' Jan said her ADHD was largely ignored in the first prison she was sent to. 'I don't think they really took that into consideration. As soon as you walk into the prison, it's like you're cut off from society and everything stops.' 'There needs to be more help in closed prisons,' she said. 'If you've only got one neurodiversity lead and they're not doing their job, you're letting down 150 people.' Conditions were better in the second prison, where staff were more responsive. 'The neurodiversity lead in the open prison was very invested in me,' Jan said. 'She said she felt like I was in the criminal justice system for the wrong reasons, like the system had failed me.' Gaps in Post-Release Support Jan's challenges continued after her release. 'I've found it very difficult to handle changes,' she said. Frequent housing moves disrupted referrals. 'There just seems to be some sort of drop in the system when you're released.' Confusion over probation conditions also caused distress. On several occasions she has said to her probation officer, 'please, just send me back to jail.' Young pointed out that many former inmates struggle to access care, lacking even a registered GP to renew prescriptions. According to the MoJ, entrants to the prison system should receive an initial health screen within 24 hours. This is followed by a full health assessment within 7 days. This provides 'opportunities for identification of known conditions or needs, as well as capturing any required reasonable adjustments,' Medscape News UK was told. Although HMPPS takes a needs-led approach to supporting people in prison, they 'would not attribute any additional needs that are identified during the screening process to a specific clinical condition ourselves but do encourage individuals to self-declare any conditions or needs they consider themselves to have.' HMPPS introduced the neurodiversity support manager (NSM) role in 2021 to improve support for people with ADHD and other neurodivergent conditions while they were behind bars. NSMs were responsible for providing training and guidance to prison staff to help them not only identify prisoners who may need extra support, but also to ensure that neurodivergent prisoners had access to appropriate education, skills and work opportunities within the prison. Communication and understanding was a big issue for Jan: 'Some of my licence conditions they've put there haven't really been explained. So, I've then done things that have potentially breached my licence without knowing it.' Does Medication Help? The evidence on whether medication reduces reoffending is mixed. Asherson and colleagues conducted a large randomised double-blind trial in the UK to assess the effects of methylphenidate on ADHD in a prison population. However, the results were null, which was somewhat unexpected. 'It was a bit surprising at the time because prior research had suggested there was a very large effect of medication,' Asherson said. Asherson referred to a large Swedish trial that found lower reoffending among offenders treated for ADHD. There were also data to show that they were less likely to show violent behaviour. Data are conflicting as to whether treating people diagnosed with medication while in prison actually has an influence on their overall outcomes. Calls for Change Young told Medscape News UK : 'There's so much research. There's so many arguments,' that ADHD is prevalent in the prison population and that it urgently needs addressing. Like Asherson, Young also sat on the NICE ADHD guideline working group and noted that research was not being translated into practice. One issue is the lack of data. When Medscape News UK contacted the MoJ under a freedom of information (FOI) request to ask how many people within the prison system had a diagnosis of ADHD, the response received was that clinical diagnoses of neurodevelopmental conditions such as ADHD fell under the remit of NHS England. NHS England published its first national-level data on ADHD prevalence and assessment as recently as May 2025. The document acknowledged the need to improve data quality. Henry Shelford Henry Shelford, the chief executive of ADHD UK, criticised the delay, noting that NICE first published guidelines for ADHD in the year 2000. 'For NHS England to take 25 years to create any population estimate is an expression of their abject failure to properly manage and resource ADHD,' he told The Guardian . Takeda, a pharmaceutical company which manufactures several drugs for treating ADHD, has been campaigning for better ADHD recognition in the criminal justice system for several years. In 2024, it filed freedom of information requests with 44 prisons. Only seven (16%) replied, and none could provide data on ADHD diagnoses, screening practices, staff training, or prisoner support. Young called the results 'really frustrating.' 'I've been at this since the mid 90s, and it just seems to be cyclical. I just think, when is something going to be done?' Is Reform Finally on the Way? There are some signs that change may be coming. In March 2024, NHS England launched a national task force to examine system-wide ADHD challenges, including access, diagnosis, and care pathways. While not specifically focused on the criminal justice system, its first interim report in June 2025, highlighted the need for 'cross-agency and cross-government department working focused on the whole person' and early recognition of neurodivergent conditions. Young welcomed the effort but warned that clinicians and professionals should consider the wider consequences of having the condition. 'They may be seeing people with ADHD, but they just don't know it,' Young said. 'We don't routinely ask, 'have you committed a crime?' 'Have you ever been convicted of something?' But perhaps we should.' Young acknowledged she had received speakers' fees from Takeda, and previously from Eli Lilly & Company, Flynn Pharma, Janssen, Novartis and Shire. She had also received research grants from Eli Lilly & Company, Janssen, and Shire. Asherson has consulted for Eli-Lilly & Company, Flynn Pharma Jannsen-Cilag, and Shire.
